Clinical efficacy and safety of parenteral nutrition in hematopoietic stem cell transplantation: results of a single-center randomized controlled study

Abstract

BACKGROUND: Hematopoietic stem cell transplantation frequently necessitates nutritional support. However, the safety and tolerance of parenteral nutrition have not been adequately examined, except for its association with infectious complications.

AIM: To evaluate the impact of parenteral nutrition on nutritional status and its correlation with complications during the early period following hematopoietic stem cell transplantation.

MATERIALS AND METHODS: From 2019–2020, 125 recipients of autologous (n=38) and allogeneic (n=87) hematopoietic stem cell transplantation were included in the study with a median age of 20 years (2–65). The chosen cohort included patients with leukemia (n=67), solid tumors (n=32), dysplasia (n=15) and lymphoproliferation (n=11). The control group (n=55) was composed of patients who did not depend on nutritional support. Parenteral nutrition was administered to the primary group (n=70) using second-generation (n=22) and third-generation (n=24) fat emulsions. In the event of contraindications, parenteral nutrition was administered without fat emulsions (n=24). To mitigate the risk of side effects, the initial dose of parenteral nutrition was 50%, with the achievement of the complete dose by the third day of therapy.

RESULTS: In 95.7% of cases, mucositis was the indication for parenteral nutrition. The duration of parenteral nutrition was 2–31 days (median, 11 days). In 58.6% of cases, parenteral nutrition was initiated against the background of nausea and vomiting. During the escalation of the parenteral nutrition dose, increased nausea was observed in 7.1% of patients. Side effects were noted in 22.9% of cases: hyperglycemia (n=7), vomiting (n=6) and hypertriglyceridemia (n=3). Four patients developed complications associated with parenteral nutrition, and nutritional therapy was discontinued in 20% of cases (n=14). After hematopoietic stem cell transplantation, the primary clinical efficacy criterion, body mass index, was observed to decline in each observation group. However, it recovered by day 28 and did not differ between the comparison groups as follows: the control group — from 22.7±6.4 to 21.7±6.1 kg/m², (p=0.42); group “2 in 1” — from 23.4±6.1 to 21.6±4 kg/m², (p=0.56); group provided with parenteral nutrition employing second-generation fat emulsions — from 18,8±4,9 to 18.7±4.4 kg/m², (p=0.72); group administered parenteral nutrition with third-generation fat emulsions — from 18.6±4.2 to 18.3±3.5 kg/m², (p=0.84). The febrile neutropenia rate was 75.2% and did not vary in the control and comparison groups (p=0.54). The incidence of sepsis was 24.8% and was not influenced by the use of parenteral nutrition (p=0.07). Furthermore, sepsis risk was higher when administering parenteral nutrition “2 in 1” compared to fat emulsions-containing parenteral nutrition (p=0.002). The overall frequency of acute graft versus host disease was 16.1% and was similar in the comparison groups (p=0.65).

CONCLUSION: In the cohort of patients treated with hematopoietic stem cell transplantation, parenteral nutrition regimens supplemented with second- and third-generation fat emulsions with a stepwise dose increase varied in acceptable tolerance, infection-related complications, and immunological safety, as well as effectively maintained nutritional status parameters.

Keywords

hematopoietic stem cell transplantation / parenteral nutrition

References

[1] Casirati A, Salcedo I, Cereda E, et al. The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT. Bone Marrow Transplant. 2023;58(9):965–972. doi: 10.1038/s41409-023-02018-z

[2] Casirati A., Salcedo I., Cereda E., et al. The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT // Bone Marrow Transplant. 2023. Vol. 58, N 9. P. 965–972. doi: 10.1038/s41409-023-02018-z

[3] Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition. 2017;36:11–48. doi: 10.1016/j.clnu.2016.07.015

[4] Arends J., Bachmann P., Baracos V., et al. ESPEN guidelines on nutrition in cancer patients // Clinical Nutrition. 2017. Vol. 36. P. 11–48. doi: 10.1016/j.clnu.2016.07.015

[5] Baumgartner A, Bargetzi A, Zueger N, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation — a systematic review. Bone Marrow Transplant. 2017;52:506–513. doi: 10.1038/bmt.2016.310

[6] Baumgartner A., Bargetzi A., Zueger N., et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation — a systematic review // Bone Marrow Transplant. 2017. Vol. 52. P. 506–513. doi: 10.1038/bmt.2016.310

[7] Baumgartner A, Schuetz P. Nutritional support. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic stem cell transplantation and cellular therapies. Cham (CH): Springer; 2019. P:171–176. doi: 10.1007/978-3-030-02278-5

[8] Baumgartner A., Schuetz P. Nutritional support. In: Carreras E., Dufour C., Mohty M., Kröger N., editors. The EBMT Handbook: Hematopoietic stem cell transplantation and cellular therapies. Cham (CH) : Springer, 2019. P. 171–176. doi: 10.1007/978-3-030-02278-5

[9] Baumgartner A, Hoskin K, Schuetz P. Optimization of nutrition during allogeneic hematologic stem cell transplantation. Current Opinion in Clinical Nutrition and Metabolic Care. 2018;21(3):152–158. doi: 10.1097/MCO.0000000000000461

[10] Baumgartner A., Hoskin K., Schuetz P. Optimization of nutrition during allogeneic hematologic stem cell transplantation // Current Opinion in Clinical Nutrition and Metabolic Care. 2018. Vol. 21, N 3. P. 152–158. doi: 10.1097/MCO.0000000000000461

[11] Skaarud KJ, Veierød MB, Lergenmuller S, et al. Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients. Bone Marrow Transplantation. 2019;54(12):2102–2109. doi: 10.1038/s41409-019-0638-6

[12] Skaarud K.J., Veierød M.B., Lergenmuller S., et al. Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients // Bone Marrow Transplantation. 2019. Vol. 54, N 12. P. 2102–2109. doi: 10.1038/s41409-019-0638-6

[13] Reese MK, Hewlings S. Enteral versus parenteral use in adult patients undergoing hematopoietic stem cell transplantation. Clinical Journal of Oncology Nursing. 2019;23(2):173–179. doi: 10.1188/19.CJON.173-179

[14] Reese M.K., Hewlings S. Enteral versus parenteral use in adult patients undergoing hematopoietic stem cell transplantation // Clinical Journal of Oncology Nursing. 2019. Vol. 23, N 2. P. 173–179. doi: 10.1188/19.CJON.173-179

[15] Skaarud KJ, Hjermstad MJ, Bye A, et al. Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial. Clinical Nutrition ESPEN. 2018;28:59–66. doi: 10.1016/j.clnesp.2018.08.002

[16] Skaarud K.J., Hjermstad M.J., Bye A., et al. Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial // Clinical Nutrition ESPEN. 2018. Vol. 28. P. 59–66. doi: 10.1016/j.clnesp.2018.08.002

[17] Common Terminology Criteria for Adverse Events (CTCAE). In: Myeloma UK [Internet]. 2017 [cited 2024 Jul 26]. Available from: https://academy.myeloma.org.uk/wp-content/uploads/2015/04/CTCAE_v5.pdf

[18] Common Terminology Criteria for Adverse Events (CTCAE). В: Myeloma UK [Internet]. 2017. Режим доступа: https://academy.myeloma.org.uk/wp-content/uploads/2015/04/CTCAE_v5.pdf Дата обращения: 26.07.2024.

[19] Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L. Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents. Pharmacotherapy. 2006;26:1221–1231. doi: 10.1592/phco.26.9.1221

[20] Dupuis L.L., Taddio A., Kerr E.N., Kelly A., MacKeigan L. Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents // Pharmacotherapy. 2006. Vol. 26. P. 1221–1231. doi: 10.1592/phco.26.9.1221

[21] Snegovoi AV, Larionova VB, Kononenko IB, et al. Prevention of nausea and vomiting in oncology. Clinical Oncohematology. Basic Research and Clinical Practice. 2016;9(1):75–83. EDN: VTIPHT

[22] Снеговой А.В., Ларионова В.Б., Кононенко И.Б., и др. Профилактика тошноты и рвоты в онкологии // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016. Т. 9, № 1. C. 75–83. EDN: VTIPHT

[23] Seattle Cancer Care Alliance. Hematopoietic stem cell transplantation nutrition care criteria. 2nd ed. Seattle, Wash: Seattle Cancer Care Alliance; 2002.

[24] Seattle Cancer Care Alliance. Hematopoietic stem cell transplantation nutrition care criteria. 2nd ed. Seattle, Wash : Seattle Cancer Care Alliance, 2002.

[25] Luft VM, Bagnenko SF, Shcherbuk YuA, editors. Clinical nutrition of patients in intensive care medicine: a practical guide. Saint Petersburg: Sankt-Peterburgskii NII skoroi pomoshchi im. I.I. Dzhanelidze; 2010. (In Russ).

[26] Клиническое питание больных в интенсивной медицине: практическое руководство / под ред. Луфта В.М., Багненко С.Ф., Щербука Ю.А. Санкт-Петербург : Санкт-Петербургский НИИ скорой помощи им. И.И. Джанелидзе, 2010.

[27] Leiderman IN, Yaroshetskii AI, Kokarev EA, Mazurok VA. Parenteral nutrition: Questions and answers: A guide for clinicians. Saint Petersburg: Only-Press; 2016. (In Russ).

[28] Лейдерман И.Н., Ярошецкий А.И., Кокарев Е.А., Мазурок В.А. Парентеральное питание: Вопросы и ответы: Руководство для врачей. Санкт-Петербург : Онли-Пресс, 2016.

[29] Thorvaldson L, Remberger M, Winiarski J, et al. HLA, GVHD, and parenteral nutrition are risk factors for hepatic complications in pediatric HSCT. Pediatr Transplant. 2016;20:96–104. doi: 10.1111/petr.12623

[30] Thorvaldson L., Remberger M., Winiarski J., et al. HLA, GVHD, and parenteral nutrition are risk factors for hepatic complications in pediatric HSCT // Pediatr Transplant. 2016. Vol. 20. P. 96–104. doi: 10.1111/petr.12623

[31] Chascione C, Elwyn DH, Davila M, et al. Effect of carbohydrate intake on de novo lipogenesis in human adipose tissue. Am J Physiol. 1987;253(6 Pt 1):664–669. doi: 10.1152/ajpendo.1987.253.6.E664

[32] Chascione C., Elwyn D.H., Davila M., et al. Effect of carbohydrate intake on de novo lipogenesis in human adipose tissue // Am J Physiol. 1987. Vol. 253 (6 Pt 1). P. 664–669. doi: 10.1152/ajpendo.1987.253.6.E664

[33] Visschers RGJ, Olde Damink SWM, Schreurs M, et al. Development of hypertriglyceridemia in patients with enterocutaneous fistulas. Clin Nutr. 2009;28(3):313–317. doi: 10.1016/j.clnu.2009.03.001

[34] Visschers R.G.J., Olde Damink S.W.M., Schreurs M., et al. Development of hypertriglyceridemia in patients with enterocutaneous fistulas // Clin Nutr. 2009. Vol. 28, N 3. P. 313–317. doi: 10.1016/j.clnu.2009.03.001

[35] van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–1367. doi: 10.1056/NEJMoa011300

[36] van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients // N Engl J Med. 2001. Vol. 345, N 19. P. 1359–1367. doi: 10.1056/NEJMoa011300

[37] Gogoleva TA, Kucher MA, Bogomolnyi MP. Silicone medical adhesive removal for central venous catheter care optimization in patients with haematology diseases. Cellular Therapy and Transplantation (CTT). 2023;12(1):46–50. doi: 10.18620/ctt-1866-8836-2023-12-1-46-50

[38] Gogoleva T.A., Kucher M.A., Bogomolnyi M.P. Silicone medical adhesive removal for central venous catheter care optimization in patients with haematology diseases // Cellular Therapy and Transplantation (CTT). 2023. Vol. 12, N 1. P. 46–50. doi: 10.18620/ctt-1866-8836-2023-12-1-46-50

RIGHTS & PERMISSIONS

Eco-Vector